T-cell Acute Lymphoblastic Leukemia with del (7) (q11.2q22) and Aberrant Expression of Myeloid Markers

Ahmad Ahmadzadeh1, Sajedeh Saedi2, Kaveh Jaseb2*, Ali Amin Asnafi2, Arash Alghasi2, Najmaldin Saki2
1Cancer, Petroleum and Environmental Pollutants Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Corresponding author: Kaveh Jaseb M.D
Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Email: k_jaseb@yahoo.com

Received: 4, Jul, 2013
Accepted: 26, Jul, 2013

ABSTRACT
T cell acute lymphoblastic leukemia (ALL) is an invasive disease with a higher incidence in children and adolescents. In terms of Immunophenotype, T-ALL is positive for CD2, CD7, CD34 and HLA-DR, and the level of these markers is increased with increasing age. In addition, the myeloid markers (CD13, CD33) are sometimes expressed in T-ALL. In this study, we introduce a rare case of a 28-year-old woman with T-ALL with aberrant expression of myeloid markers (CD13), without lymphadenopathy and with 94% blasts in bone marrow specimens. The patient has the rare karyotype of 46,XX del(7)(q11.2q22). The presence of del7 is a rare phenomenon in T-ALL.

KEY WORDS: Acute lymphoblastic leukemia, Myeloid, T cell

INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. There are two subtypes of ALL: 1-Acute lymphoblastic leukemia of T cells 2-Acute lymphoblastic leukemia of B cells.1, 2 T-ALL is an aggressive cancer, which mainly occurs in children and adolescents. T-ALL is more common in men than women, with a prevalence of 10-15% in children and 25% in adults.3, 4 T-ALL occurs due to acquired chromosomal translocations and other genetic and epigenetic abnormalities in T lymphoblasts, leading to aberrant expression of specific transcription factors such as: HOX11, TAL1/SCL and LYL1 oncogenic transcription factors.5, 6 Characteristic features of T-ALL include a large number of blasts in peripheral blood and bone marrow, enlarged lymph nodes in mediastinum and frequent involvement of central nervous system.7 Although the outcome of disease has improved using current treatments but, five-year survival rate is 50-60%.8 Immunophenotyping of ALL shows positive TdT in pre T ALL and likely expression of CD10, CD79a and cCD3 markers. Although myeloid markers (CD13-CD33) may be expressed, expression of CD117 is a rare phenomenon.1 In one study, CD7 expression has been indicated in all cases of T-ALL, while the level of CD2 is decreased with increasing age, and HLA-DR and CD34 level is increased with age.9 Molecular analysis of common genetic changes in leukemia cells leads to better understanding of the pathogenesis and prognosis of ALL, although the prevalence of genetic changes is different in children and adults.10 More than 50% of T-ALL cases show mutations in NOTCH1 gene, an important regulator of growth in normal T cells.11

We describe a case of T-ALL with aberrant expression of myeloid antigens along with the rare karyotype of del7 (q11) in a young woman.
Complete loss of chromosome 7 (-7) or deletion in q arm of this chromosomes is common in malignant myeloid disorders (AML and MDS), and del(7) (q11.2q22) has been rarely reported in T-ALL.\textsuperscript{12-14} We discuss the expression of this cytogenetic abnormality along with laboratory findings and prognosis of the disease.

**The Patient’s History**

A 28-year-old woman with severe lethargy visited Shafa Hospital in Ahwaz. After performing CBC, high leukocytosis (WBC=19.11×10\textsuperscript{9}/L), anemia (RBC=1.45×10\textsuperscript{12}) and thrombocytopenia (PLT=5×10\textsuperscript{9}/L) was diagnosed (other hematologic indices are given in Table 1).

|                     |   |
|---------------------|---|
| **WBC**             | 19.11×10\textsuperscript{9}/L |
| **Neu%**            | 5.4 |
| **Lym%**            | 69.6 |
| **Mon%**            | 24.7 |
| **Eos%**            | 0.1 |
| **Bas%**            | 0.2 |
| **RBC**             | 1.45×10\textsuperscript{12} |
| **HGB**             | 4.1g/dl |
| **HCT**             | 12.7% |
| **MCV**             | 87.6 Fl |
| **MCH**             | 28.3 Pg |
| **MCHC**            | 32.3 g/Dl |
| **PLT**             | 5×10\textsuperscript{9}/L |

Abbreviation: Neu(Neutrophil); Lym(Lymphocyte), Mon(Monocyte), Eos(Eosinophil), Bas(Basophil)

The patient had no significant medical history except postpartum anemia. No abnormality was detected in ultrasound examination of the abdomen and pelvis, and lymph node enlargement was not seen in patient’s radiography. Biochemical and serologic examination showed high LDH (583 IU/L) level, negative direct and indirect Coomb’s test and very high ferritin levels (900.9 ng/ml). 94% blasts in the bone marrow smear was estimated (Figure 1), and myeloperoxidase staining (MPO) was negative in these blasts. Flow cytometry indicated the expression of CD34 (60%), CD117 (17%), HLA-DR (82%), CyCD3 (85%), CD7 (85%), CD2 (89%), CD13 (59%) and CD33 (5%) markers by blasts, and other markers were negative in them. In cytogenetic examination of the patient, 46,XX del(7)(q11.2q22) was detected (Figure 2).

Simultaneous expression of myeloid and lymphoid markers on blasts along with presence of del(7)(q11.2q22) specific for acute myeloid leukemia (which is rarely reported in T-ALL) complicated the diagnosis. At first, two-phenotype acute leukemia was suspected, but it was ruled out in further investigation as the most common myeloid markers in acute two-phenotype leukemia are CD33, CD13, CD15 (CD19, CD79a, CD22 for B lymphocytes and CYCD3, CD7, CD2 for T lymphocytes), but in this patient myeloid and B lymphocyte markers were not expressed or had a low level of expression. Considering high expression of T lymphocyte markers and positive PAS staining
in the blasts, final diagnosis was T-ALL with aberrant expression of CD13 and del(7)(q11.2q22). The patient underwent chemotherapy with treatment protocol of endoxane, doxorubicin, prednisone and vincristine for ALL. Flow cytometry was performed one month later (1/2013), and non-conclusive bone marrow with erythroid hyperplasia was diagnosed. Response to treatment was good, but the patient became BM transplant candidate because of high risk. After finding an individual with similar HLA, the patient underwent BM transplantation, and is currently in remission (3/2013).

DISCUSSION

T-ALL is an aggressive cancer causing 10-15% of ALL cases in children and 25% in adults. Aberrant phenotype (MY+ALL) has been reported in 10-47% of ALL cases. CD33 myeloid antigen has been detected in 39% of adult B-ALL cases and 33% of T-ALL cases. Common myeloid antigens in ALL are shown in Table 2. ALL cases expressing CD13 and CD33 myeloid antigens are associated with a favorable outcome in adults, with a poor outcome in B-ALL but not in T-ALL. In another study on ALL, approximately 20% of the patients showed simultaneous expression of T and myeloid antigens, and no difference in response or survival was observed between patients with or without myeloid antigen who expressed T antigens. In this paper, we have studied an ALL patient with aberrant expression of myeloid antigens and rare karyotype of del(7)(q11.2q22). Heerema et al., in their study concluded that the survival rate was not different in adult ALL patients with or without deletion of chromosomes 5 and 7 but the disease outcome was unfavorable. Monosomy 7 and del(7q) are associated with poor outcome in AML. del(7p) in ALL in children is associated with poor outcome but deletion of 7q is not. Deletion in chromosome 7 and monosomy of 7 has been reported in adult ALL, and there are reports of deletion in 7q11.2 and 7q11 in ALL. In 1977, a case of ALL with Philadelphia chromosome and abnormalities of chromosome 7 [monosomy 7 in 60% of blasts and del (7q11) in a small percentage of the cells] was reported. Abnormalities of chromosome 7 are associated with impaired granulocyte movement, susceptibility to infection, rapid disease progression and poor response to treatment. In this case, we did not detect any infection and the patient’s response to treatment was good. 7/del (7q) occurs in three cases: 1- in patients with spontaneous MDS/AML, 2- in treatment dependent MDS/AML or occupational/environmental exposure to mutagens, 3-leukemia arising from individual susceptibility to AML, Fanconi’s anemia, congenital neutropenia and NF1 commonly detected with -7/del (7q). Loss of chromosome 7 or deletion in long arm of this chromosome is common in MDS in children and adults, and is in fact the most common cytogenetic abnormality in children MDS, detected in 30% of the cases. The long arm of chromosome 7 contains some tumor suppressor genes, and these genes are probably located on loci usually deleted in patients with del7. Important regions of chromosome 7 include 7q22 and 7q32-33.

CONCLUSION

Deletion detection in various regions of chromosome 7 in T and even B acute lymphoblastic leukemia demonstrates the applicability of deletions in this chromosome for disease diagnosis and prognosis. T-ALL with aberrant expression of myeloid antigens is not different from T-ALL without the expression of myeloid antigens in view of outcome. According to good response of our patient to therapy, deletion in q11 region of chromosome 7 is likely to be associated with a favorable prognosis and response to therapy; however, based on previous findings, del7 is associated with poor response to treatment. Table 3 shows deletions in different regions of chromosome 7 in various types of leukemia.

ACKNOWLEDGEMENT

We wish to thank all our colleagues in shafa hospital.
Table 2. Specific CD Markers of ALL Subtypes and Common Myeloid Markers in ALL

| Immuno phenotype | Lymphoid Ag | Myeloid Ag                      | Prognosis | Reference |
|------------------|------------|---------------------------------|-----------|-----------|
| T-ALL            | CD3-CD5-CD7| CD13(12.2)-CD33(9.8)-CD14(6.5)- | Good      | (24-26)   |
|                  |            | CD11b(9.8)-CD65(10.6)           |           |           |
| B-ALL            | CD19-CD20- | CD13(20.3)-CD33(16.7)-CD14(10.8)- | Poor      |           |
|                  | CD22-CD34- | CD11b(6.4)-CD65(12.4)           |           |           |
|                  | HLA-DR     |                                 |           |           |

Abbreviation: T-ALL (T cell acute lymphoblastic leukemia); B-ALL (B cell acute lymphoblastic leukemia)

Table 3. Deletion in Different Regions of Chromosome 7 in Different Types of Leukemia

| ALL       | CLL       | AML       | CML       | MDS       | Reference |
|-----------|-----------|-----------|-----------|-----------|-----------|
| Del7(q11) | Del7(q11) | Del7(q11) | Del7(q11) | Del7(q11) | (28,27,22) |
| Del7(q22) | Del7(q22) | Del7(q22) | Del7(q11.2q22) | Del7(q22) |           |
| Del7(q32-36)| Del7(q31) | Del7(q22) | Del7(q22) | Del7(q34) |           |
| Del7(p15) | Del7(q32) | Del7(q32) | Del7(q32) | Del7(q2q36)|           |
| Del7(p13-15)| Del7(q34) | Del7(q34) | Del7(q35) | Del7(q35) |           |
| Del7(q11q32)| Del7(q21) | Del7(q21) | Del7(q21) | Del7(q21) |           |
| Del7(q11q36)| Del7(q22q32)| Del7(q22q32)| Del7(q22q32)| Del7(q22q32)|           |
| Del7(q22q36)| Del7(q22q36)| Del7(q22q36)| Del7(q22q36)| Del7(q22q36)|           |
| Del7(q34)| Del7(q34) | Del7(q34) | Del7(q34) | Del7(q34) |           |
| Del7(q32)| Del7(q32) | Del7(q32) | Del7(q32) | Del7(q32) |           |
| Del7(p15)| Del7(p15) | Del7(p15) | Del7(p15) | Del7(p15) |           |
| Del7(q11)| Del7(q11) | Del7(q11) | Del7(q11) | Del7(q11) |           |
| Del7(q22q36)| Del7(q22q36)| Del7(q22q36)| Del7(q22q36)| Del7(q22q36)|           |
| Del7(q11q36)| Del7(q11q36)| Del7(q11q36)| Del7(q11q36)| Del7(q11q36)|           |

REFERENCES

1. Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Experimental and molecular pathology. 2007; 83(3):471-3.

2. Mullighan CG, Willman CL. Advances in the Biology of Acute Lymphoblastic Leukemia—From Genomics to the Clinic. Journal of Adolescent and Young Adult Oncology. 2011; 1(2):77-86.

3. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012; 122(10):3398.

4. Speleman F, Cauwelier B, Dastugue N, Cools J, Verhasselt B, Poppe B, et al. A new recurrent inversion, inv (7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia. 2005; 19(3):358-66.

5. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-71.

6. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002; 1(1):75-87.

7. Cauwelier B, Cavé H, Gervais C, Lessard M, Barin C, Perot C, et al. Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRβ-HOXA rearrangement: a study of the Groupe Francophone de Cytogenetique Hematologique. Leukemia. 2006; 21(1):121-8.

8. Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K, et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2009; 113(17):3918-24.

9. Ma J, Liu Y, Chen S, Zhang Q, Sun L, Liu L, et al. Immunophenotyping characteristics of adult patients with acute lymphoblastic leukemia in different ages. Zhongguo shi yan xue ye xue za zhi/Zhongguo bing li sheng li xue hui= Journal of experimental hematology/Chinese Association of Pathophysiology. 2010; 18(4):942.
10. Pui C-H, Relling MV, Downing JR. Acute lymphoblastic leukemia. New England Journal of Medicine. 2004; 350(15):1535-48.

11. Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. The Lancet. 2008; 371(9617):1030-43.

12. Heerema N, Nachman J, Sather H, La M, Hutchinson R, Lange B, et al. Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group. Leukemia. 2004; 18(5):939-47.

13. Mandel E, Shabtai F, Gafter U, Klein B, Halbrecht I, Djaldetti M. Ph1-positive acute lymphocytic leukemia with chromosome 7 abnormalities. Blood. 1977; 49(2):281-7.

14. Luna-Fineman S, Shannon KM, Lange BJ. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood. 1995; 85(8):1985-99.

15. Owaidah T, Al Beihany A, Iqbal M, Elkum N, Roberts G. Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia. 2006; 20(4):620-6.

16. Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GiMema ALL 0496 trial. Haematologica. 2007; 92(3):342-8.

17. Bhushan B, Chauhan PS, Saluja S, Verma S, Mishra AK, Siddiqui S, et al. Aberrant phenotypes in childhood and adult acute leukemia and its association with adverse prognostic factors and clinical outcome. Clinical and experimental medicine. 2010; 10(1):33-40.

18. Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. New England Journal of Medicine. 1987; 316(18):1111-7.

19. Kere J, Ruutu T, Davies K, Roninson I, Watkins P, Winqvist R, et al. Chromosome 7 long arm deletion in myeloid disorders: a narrow breakpoint region in 7q22 defined by molecular mapping. Blood. 1989; 73(1):230-4.

20. Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Hurwitz CG, et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer. 1997; 79(7):1438-46.

21. Preiss BS, Hasle H, Sørensen AG, Heil M, Knudstrup GB. A case of childhood acute myeloid leukemia associated with inversion (7)(p21q31). Cancer genetics and cytogenetics. 1999; 108(2):144-8.

22. Beaum A, Davis E, Eisenbart J, Larson R, Green E. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 1996; 88(6):1930-5.

23. Kim YG, Cho SY, Park TS, Oh SH, Yoon H-J. Therapy-related myelodysplastic syndrome/acute myeloid leukemia with del (7)(q22) in a patient with de novo AML. Annals of Clinical & Laboratory Science. 2011; 41(1):79-83.

24. Wiersma SR, Ortega J, Sobel E, Weinberg KL. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. New England Journal of Medicine. 1991; 324(12):800-8.

25. Tiensiwakul P, Lertlum T, Nuchprayoon I, Seksarn P. Immunophenotyping of acute lymphoblastic leukemia in pediatric patients by three-color flow cytometric analysis. Asian Pacific Journal of Allergy and Immunology. 1999; 17:17-22.

26. Putti MC, Rondelli R, Cocito MG, Arocó M, Sainati L, Conter V, et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood. 1998; 92(3):795-801.

27. Fischer K, Fröhling S, Scherer SW, Brown JM, Scholl C, Stilgenbauer S, et al. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood. 1997; 89(6):2036-41.

28. Döhnner K, Brown J, Hehmann U, Hetzel C, Stewart J, Lowther G, et al. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood. 1998; 92(11):4031-5.